当前位置: X-MOL 学术Eur. Thyroid. J. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cardiac Metastasis from Medullary Thyroid Cancers with Long-Term Survival under Vandetanib
European Thyroid Journal ( IF 3.5 ) Pub Date : 2021-08-25 , DOI: 10.1159/000517716
Camille Buffet 1, 2 , Sophie Leboulleux 3 , Françoise Kraeber-Bodéré 4, 5 , Caroline Bodet-Milin 4, 5 , Laure Cabanes 6, 7 , Anthony Dohan 8, 9 , Pascal Leprince 10 , Martin Schlumberger 2, 11 , Olivier Huillard 12, 13 , Lionel Groussin 7, 14, 15
Affiliation  

Background: Cardiac metastases from thyroid cancers are uncommon with a poor prognosis. There is a lack of long-term follow-up studies. Cases: We report 2 cases of cardiac metastasis from medullary thyroid cancer (MTC). Both patients presented limited metastatic disease apart from a cardiac metastasis. The initial diagnosis was challenging and was facilitated by functional imaging with an immuno-PET-CT using an anti-CEA bispecific antibody and a 68Ga-labeled peptide. Both patients were treated with the multitarget kinase inhibitor vandetanib with prolonged stability. The first patient was alive at the last follow-up, 14 years after the diagnosis of cardiac metastasis. The second patient required surgical excision of the cardiac mass because of disease progression under vandetanib. Conclusion: These cases illustrate long-term survival and effectiveness of clinical management of 2 patients who developed cardiac metastases from MTC, in the current era of personalized medicine with targeted therapy.
Eur Thyroid J


中文翻译:

甲状腺髓样癌的心脏转移在凡德他尼下长期存活

背景:甲状腺癌的心脏转移并不常见,预后较差。缺乏长期随访研究。病例:我们报告了 2 例甲状腺髓样癌 (MTC) 的心脏转移病例。除心脏转移外,两名患者均表现出有限的转移性疾病。初步诊断具有挑战性,并通过使用抗 CEA 双特异性抗体和68Ga标记的肽。两名患者都接受了多靶点激酶抑制剂凡德他尼的治疗,具有延长的稳定性。在诊断心脏转移14年后,第一个患者在最后一次随访中还活着。第二名患者需要手术切除心脏肿块,因为在凡德他尼下疾病进展。结论:这些病例说明了在当前个性化医疗和靶向治疗时代,2 例 MTC 心脏转移患者的长期生存和临床管理的有效性。
欧洲甲状腺杂志
更新日期:2021-08-25
down
wechat
bug